PT  - JOURNAL ARTICLE
AU  - Gerald B. Appel
TI  - New and future therapies for lupus nephritis
AID  - 10.3949/ccjm.78gr.11004
DP  - 2012 Feb 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 134--140
VI  - 79
IP  - 2
4099  - http://www.ccjm.org/content/79/2/134.short
4100  - http://www.ccjm.org/content/79/2/134.full
SO  - Cleve Clin J Med2012 Feb 01; 79
AB  - Based on data from randomized controlled trials over the past decade, oral mycophenolate (CellCept) now rivals intravenous cyclophosphamide (Cytoxan) as a first-line therapy for lupus nephritis, offering similar efficacy but less toxicity. The roles of rituximab (Rituxan) and new immunomodulatory agents are being explored. Creativity in treating lupus nephritis is needed; one regimen does not fit all.